DexCom, Inc. $DXCM Shares Bought by Brighton Jones LLC

Brighton Jones LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 5.3% during the second quarter, HoldingsChannel reports. The institutional investor owned 17,917 shares of the medical device company’s stock after purchasing an additional 908 shares during the quarter. Brighton Jones LLC’s holdings in DexCom were worth $1,564,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Linden Thomas Advisory Services LLC lifted its position in DexCom by 18.9% in the second quarter. Linden Thomas Advisory Services LLC now owns 28,038 shares of the medical device company’s stock valued at $2,447,000 after buying an additional 4,455 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its position in DexCom by 75.4% in the second quarter. Kornitzer Capital Management Inc. KS now owns 99,189 shares of the medical device company’s stock valued at $8,658,000 after buying an additional 42,652 shares during the last quarter. Shaker Investments LLC OH lifted its position in DexCom by 116.0% in the second quarter. Shaker Investments LLC OH now owns 47,737 shares of the medical device company’s stock valued at $4,167,000 after buying an additional 25,638 shares during the last quarter. AG2R LA Mondiale Gestion D Actifs lifted its position in DexCom by 2.9% in the second quarter. AG2R LA Mondiale Gestion D Actifs now owns 18,762 shares of the medical device company’s stock valued at $1,638,000 after buying an additional 523 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC acquired a new position in DexCom in the second quarter valued at about $317,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent analyst reports. Mizuho upped their target price on shares of DexCom from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Friday. Raymond James Financial boosted their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. Finally, Truist Financial cut their price target on shares of DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $97.19.

Insider Activity

In related news, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,383 shares of company stock valued at $434,274 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Down 1.0%

DXCM stock opened at $70.33 on Monday. The company’s 50 day moving average price is $72.37 and its 200 day moving average price is $77.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a market capitalization of $27.58 billion, a price-to-earnings ratio of 48.84, a PEG ratio of 1.48 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the firm earned $0.43 earnings per share. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.